Pfizer unveils new $1b manufacturing facility in Tuas Biomedical Park

The facility spans 429,000 sq ft.

Pfizer has launched its $1b Active Pharmaceutical Ingredient (API) manufacturing facility in Tuas Biomedical Park.

The facility spans 429,000 sq ft and will produce small molecule APIs for Pfizer’s oncology, pain, and antibiotic medicines globally. The expansion will also create over 250 jobs.

Construction began in 2020 and was designed to accommodate future additions such as processing suites, dry-end suites, dispensaries, a warehouse, and ancillary equipment.

Design priorities included integrating systems and technologies to increase energy efficiency and manage energy demand effectively. The facility also holds a Green Mark Gold certification.

Follow the link for more news on

Pfizer

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia